Allogene Therapeutics Inc (ALLO)

전일 마감가:

$2.86

열려 있는:

$2.84

하루 거래량:

998.31K

시가총액:

$471.20M

수익:

$95,000

순이익/손실:

$-327.27M

주가수익비율:

-1.1265

EPS:

-2.45

순현금흐름:

$-239.25M

1주 성능:

-10.10%

1개월 성능:

-32.19%

6개월 성능:

+10.40%

1년 성능:

-56.60%

1일 변동 폭

$2.74

$2.92

52주 변동 폭

$2.23

$6.89

Allogene Therapeutics Inc Stock (ALLO) Company Profile

명칭

Allogene Therapeutics Inc

부문

Healthcare (1212)

산업

Biotechnology (699)

전화

415-640-5325

주소

210 East Grand Avenue, South San Francisco

직원

90

트위터

@AllogeneTx

다음 수익 날짜

2024-06-05

최신 SEC 제출 서류

ALLO's Discussions on Twitter

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-01-05	다운그레이드	Guggenheim	Buy → Neutral
2024-01-05	다운그레이드	JMP Securities	Mkt Outperform → Mkt Perform
2023-12-08	개시	Citigroup	Buy
2023-06-26	재개	Oppenheimer	Outperform
2023-03-21	개시	Bernstein	Mkt Perform
2023-01-24	업그레이드	JP Morgan	Neutral → Overweight
2023-01-06	업그레이드	Robert W. Baird	Neutral → Outperform
2022-12-12	다운그레이드	BofA Securities	Buy → Underperform
2022-08-10	다운그레이드	Raymond James	Outperform → Mkt Perform
2022-07-15	업그레이드	Goldman	Neutral → Buy
2022-06-03	개시	Robert W. Baird	Neutral
2022-02-28	재확인	B. Riley Securities	Buy
2021-10-20	개시	Cowen	Outperform
2021-10-08	다운그레이드	Goldman	Buy → Neutral
2021-10-08	다운그레이드	Stifel	Buy → Hold
2021-09-23	업그레이드	Raymond James	Mkt Perform → Outperform
2021-06-21	재개	Jefferies	Buy
2021-05-20	업그레이드	Truist	Hold → Buy
2021-05-14	개시	B. Riley Securities	Buy
2021-01-26	업그레이드	Stifel	Hold → Buy
2020-12-10	재개	H.C. Wainwright	Buy
2020-11-24	개시	BofA Securities	Buy
2020-10-23	개시	RBC Capital Mkts	Outperform
2020-06-01	다운그레이드	Raymond James	Outperform → Mkt Perform
2020-05-29	재확인	H.C. Wainwright	Buy
2020-05-19	업그레이드	ROTH Capital	Neutral → Buy
2020-05-15	업그레이드	Guggenheim	Neutral → Buy
2020-05-14	재확인	H.C. Wainwright	Buy
2020-05-14	다운그레이드	SunTrust	Buy → Hold
2020-04-13	개시	SunTrust	Buy
2020-03-13	개시	H.C. Wainwright	Buy
2020-03-05	개시	Stifel	Hold
2020-02-24	개시	Berenberg	Hold
2019-12-18	개시	JMP Securities	Mkt Outperform
2019-11-04	개시	Canaccord Genuity	Buy
2019-08-09	개시	BTIG Research	Buy
2019-06-05	개시	ROTH Capital	Neutral
2019-05-31	개시	Guggenheim	Neutral
2019-05-23	개시	Stifel	Hold
2019-03-29	개시	Piper Jaffray	Overweight

모두보기

Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스

CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?

Zacks Investment Research

Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

Zacks Investment Research

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

GlobeNewswire Inc.

Omega Therapeutics, Inc. (OMGA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?

Zacks Investment Research

Allogene Therapeutics Inc (ALLO) 재무 분석

Allogene Therapeutics Inc (ALLO) 매출 2024

Allogene Therapeutics Inc (ALLO) 순이익 2024

Allogene Therapeutics Inc (ALLO) 현금흐름 2024

Allogene Therapeutics Inc (ALLO) 주당 순이익 2024

Allogene Therapeutics Inc 주식 (ALLO) 내부자 거래